Search Videos and More
Video
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study
Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Video
Ada Waks, MD Presents Results of the MARGOT Study
Dana-Farber's Ada Waks, MD presented results of MARGOT, a phase 2 trial comparing margetuximab plus chemo or trastuzumab plus chemo in patients with early stage HER2+ breast cancer.
Video
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor
Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Video
Jennifer Ligibel, MD Discusses Weigh Loss Intervention
Dana-Farber's Jennifer Ligibel, MD reviews a telephone-based weight loss intervention that led to significant improvements in metabolic and inflammatory biomarkers associated with cancer recurrence according to new data.
News
Why Zip Code Matters: How Environment Shapes Cancer Risk
Zip codes didn’t exist until 1963 and were established to help speed the delivery of mail. Today, we rely much less on paper mail but strangely, zip codes play a bigger role.
News
Dana-Farber Research News 12.15.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 through November 30.
Document
Treatment Guideline: Capivasertib Plus Fulvestrant for Advanced Estrogen Receptor-Positive Breast Cancer - Updated in 2025
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of capivasertib plus fulvestrant in patients with advanced estrogen receptor-positive breast cancer.
News
A Vision for Health Equity in Childhood Cancer
The Dana-Farber lab of Kira Bona, MD, MPH, has uncovered an alarming reality: children from low-income households are more likely to experience cancer relapse and face lower survival rates compared to their more privileged peers, despite receiving treatment on highly standardized clinical trials at top academic centers.
News
Early Detection and Interception Research Shows Promise at ASH
Dana-Farber Cancer Institute investigators are leading three separate studies with encouraging results related to the early detection and interception of multiple myeloma.
News
Dana-Farber Research News 12.01.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 1 through November 15.
Symposium
2024 SABCS Highlights
Dana-Farber Cancer Institute Faculty highlights from the 2024 San Antonio Breast Cancer Symposium.
Symposium
2024 ASH Highlights
Review presentations and information shared by Dana-Farber physician-scientists at the 67th American Society of Hematology Annual Meeting & Exposition in San Diego on Dec. 1-10th, 2024.